-
In Virtual Trials, Two Alzheimer’s Drugs Do Poor Job Of Slowing Cognitive Decline
Bio-IT World | Researchers from Duke, Penn State, and the University of Tennessee collaboratively built a mathematical model of Alzheimer’s disease that used real, de-identified patient data to simulate health outcomes from a pair of anti-amyloid-beta drugs. Notably, the virtual (aka in silico) clinical trials employed a computational approach that provides “individualized prescriptions” based on optimal timing and dosing of treatment while minimizing possible side effects.
Dec 14, 2022
-
All of Us Announces First Return of Health-Related DNA Results
Bio-IT World | The National Institutes of Health's All of Us Research Program has begun returning personalized health-related DNA results to more than 155,000 participants, with reports detailing whether participants have an increased risk for specific health conditions and how their body might process certain medications.
Dec 13, 2022
-
Pregnancy Exposome A New Frontier In Personalized Medicine
Bio-IT World | The importance of the pregnancy exposome on health was explored in depth by Barbara Cohn, Ph.D., director and senior research scientist at the Public Health Institute, at the Mayo Clinic’s recent Individualizing Medicine Conference. She has been an integral part of a groundbreaking, multigenerational study examining the ripple effects of chemical exposures on pregnant women and their offspring and the potential for metabolomics to drive individualized prevention and treatment.
Dec 13, 2022


